Age, sex, and type of medication predict the effect of anti-VEGF treatment on central retinal thickness in wet age-related macular degeneration

Toke Bek, Sidsel Ehlers Klug Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark Purpose: Randomized clinical trials studying the effects of VEGF inhibition on wet age-related macular degeneration (wAMD) are designed so that the effects of individually varying risk factors on...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bek T, Klug SE
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	wet AMD anti-VEGF treatment risk factors real life experience Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/8565da7e1e9445d1ae5fdb9db90e2457
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8565da7e1e9445d1ae5fdb9db90e2457
record_format	dspace
spelling	oai:doaj.org-article:8565da7e1e9445d1ae5fdb9db90e24572021-12-02T02:08:08ZAge, sex, and type of medication predict the effect of anti-VEGF treatment on central retinal thickness in wet age-related macular degeneration1177-5483https://doaj.org/article/8565da7e1e9445d1ae5fdb9db90e24572018-03-01T00:00:00Zhttps://www.dovepress.com/age-sex-and-type-of-medication-predict-the-effect-of-anti-vegf-treatme-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Toke Bek, Sidsel Ehlers Klug Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark Purpose: Randomized clinical trials studying the effects of VEGF inhibition on wet age-related macular degeneration (wAMD) are designed so that the effects of individually varying risk factors on the treatment response are eliminated. The influence of these risk factors can be studied in large data sets from real-life experience.Patients and methods: All 2,255 patients diagnosed with wAMD requiring anti-VEGF treatment in at least one eye over more than 9 years in a defined Danish population with 0.9 million inhabitants were studied. The predictive value of eye laterality, sex, current smoking status, type of anti-VEGF compound, membrane position, membrane type, leakage area, number of injections, number of visits, age, time to follow-up, visual acuity, and central retinal thickness (CRT) at baseline on change in CRT after three monthly injections with anti-VEGF compound followed by treatment pro re nata for up to 12 months was assessed.Results: After 12 months, 67 patients had died, 903 had had stable CRT for at least 6 months, and 1,285 patients had not achieved stable CRT. The reduction in CRT was -84.8±118.3 µm, whereas the increase in visual acuity was 2.2±14.7 Early Treatment Diabetic Retinopathy Study letters. The risk factors included contributed to 64% of the variation in CRT reduction. High age and high CRT at baseline predicted high CRT reduction, whereas more injections, treatment with ranibizumab, and male sex predicted a low CRT reduction.Conclusion: Age, sex, and type of anti-VEGF medication can be used to plan treatment and inform patients about the expected response of anti-VEGF treatment in wAMD. Keywords: wet AMD, anti-VEGF treatment, risk factors, real-life experience Bek TKlug SEDove Medical Pressarticlewet AMDanti-VEGF treatmentrisk factorsreal life experienceOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 473-479 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	wet AMD anti-VEGF treatment risk factors real life experience Ophthalmology RE1-994
spellingShingle	wet AMD anti-VEGF treatment risk factors real life experience Ophthalmology RE1-994 Bek T Klug SE Age, sex, and type of medication predict the effect of anti-VEGF treatment on central retinal thickness in wet age-related macular degeneration
description	Toke Bek, Sidsel Ehlers Klug Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark Purpose: Randomized clinical trials studying the effects of VEGF inhibition on wet age-related macular degeneration (wAMD) are designed so that the effects of individually varying risk factors on the treatment response are eliminated. The influence of these risk factors can be studied in large data sets from real-life experience.Patients and methods: All 2,255 patients diagnosed with wAMD requiring anti-VEGF treatment in at least one eye over more than 9 years in a defined Danish population with 0.9 million inhabitants were studied. The predictive value of eye laterality, sex, current smoking status, type of anti-VEGF compound, membrane position, membrane type, leakage area, number of injections, number of visits, age, time to follow-up, visual acuity, and central retinal thickness (CRT) at baseline on change in CRT after three monthly injections with anti-VEGF compound followed by treatment pro re nata for up to 12 months was assessed.Results: After 12 months, 67 patients had died, 903 had had stable CRT for at least 6 months, and 1,285 patients had not achieved stable CRT. The reduction in CRT was -84.8±118.3 µm, whereas the increase in visual acuity was 2.2±14.7 Early Treatment Diabetic Retinopathy Study letters. The risk factors included contributed to 64% of the variation in CRT reduction. High age and high CRT at baseline predicted high CRT reduction, whereas more injections, treatment with ranibizumab, and male sex predicted a low CRT reduction.Conclusion: Age, sex, and type of anti-VEGF medication can be used to plan treatment and inform patients about the expected response of anti-VEGF treatment in wAMD. Keywords: wet AMD, anti-VEGF treatment, risk factors, real-life experience
format	article
author	Bek T Klug SE
author_facet	Bek T Klug SE
author_sort	Bek T
title	Age, sex, and type of medication predict the effect of anti-VEGF treatment on central retinal thickness in wet age-related macular degeneration
title_short	Age, sex, and type of medication predict the effect of anti-VEGF treatment on central retinal thickness in wet age-related macular degeneration
title_full	Age, sex, and type of medication predict the effect of anti-VEGF treatment on central retinal thickness in wet age-related macular degeneration
title_fullStr	Age, sex, and type of medication predict the effect of anti-VEGF treatment on central retinal thickness in wet age-related macular degeneration
title_full_unstemmed	Age, sex, and type of medication predict the effect of anti-VEGF treatment on central retinal thickness in wet age-related macular degeneration
title_sort	age, sex, and type of medication predict the effect of anti-vegf treatment on central retinal thickness in wet age-related macular degeneration
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/8565da7e1e9445d1ae5fdb9db90e2457
work_keys_str_mv	AT bekt agesexandtypeofmedicationpredicttheeffectofantivegftreatmentoncentralretinalthicknessinwetagerelatedmaculardegeneration AT klugse agesexandtypeofmedicationpredicttheeffectofantivegftreatmentoncentralretinalthicknessinwetagerelatedmaculardegeneration
_version_	1718402659958915072

Age, sex, and type of medication predict the effect of anti-VEGF treatment on central retinal thickness in wet age-related macular degeneration

Ejemplares similares